Shareholder Investigation of Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (OSMT) Preliminary Results Fail to Beat Placebo
On March 27, 2019, after the markets closed, Osmotica Pharmaceuticals plc (OSMT) announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change. On this news, shares of Osmotica fell $2.74, or nearly 41%, to close at $4.00 on March 28, 2019, and has yet to recover.
Osmotica Pharmaceuticals plc (OSMT) Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.